

Konstantynów Łódzki, April 15, 2024

Press Release

Nigel Stapleton to support Mabion's sales growth in role of Business Development Director for Europe

- > **On April 15, 2024, Dr. Nigel Stapleton, a manager with international experience, assumed the role of Business Development Director for Europe at Mabion S.A.**
- > **As part of the Mabion team, Nigel Stapleton will be primarily responsible for acquiring new customers, building new markets and developing sales strategies and establishing business partnerships in Europe, including representing the Company at major industry events**
- > **Nigel Stapleton earned a PhD in immunology from the University of Amsterdam, and has more than 10 years of experience in the CDMO industry in business development positions**
- > **Over the course of his career, Nigel Stapleton has built business relationships with leading biopharmaceutical players in Europe, and has held key business development roles within leading European CDMOs - most recently at KBI Biopharma in Switzerland, and previously at HALIX B.V. in the Netherlands and the Eurofins Scientific group**
- > **He was awarded top-performing business development manager status several times**
- > **Mabion's Business Development department has 8 high-level experts who are actively pursuing new customers for CDMO services, with experienced manager Marty Henehan joining the team in February, taking the position of Business Development Director for North America**

"Dr. Nigel Stapleton's high level of competence and extensive experience gained in the CDMO industry in business development positions is an ideal complement to our sales efforts in Europe. Nigel is a professional with a proven track record of success in successfully building business recognition and skillfully converting relationships into signed contracts. We are glad that with Mabion's attractive development prospects, growth potential, rich know-how and open company culture, we convinced him to join our team". - comments Krzysztof Kaczmarczyk, Chief Executive Officer of Mabion S.A.

Dr. Nigel Stapleton holds a PhD in immunology from the University of Amsterdam. He has more than 10 years of experience in the CDMO industry in business development positions in the European market. He has been awarded top performing business development manager status several times due to his successful achievement of business goals. He has successfully led numerous Master Service Agreement (MSA) negotiation processes with numerous entities in the pharmaceutical industry, including the so-called "big pharma". In recent years, he has held key business development management positions at leading European CDMOs including KBI Biopharma in Switzerland, HALIX B.V. in the Netherlands and Eurofins Scientific Group, responsible for a portfolio of key customers from EU markets.

"Mabion is a highly innovative CDMO company with exposure to the attractive and growing biologic drug segment. It is at a very interesting point in transforming the direction of its growth, which, combined with its unique portfolio, modernized manufacturing facility and the highest quality standards, convinced me to decide to join the Company as Business Development Director for Europe. I believe that with these strengths we can attract a wide range of potential customers and create added value for them, while building a

Mabion's brand recognition in the CDMO industry in Europe," - says Dr. Nigel Stapleton, Business Development Director for Europe at Mabion S.A.

Mabion's priority is to further intensify activities directed at growth in contract manufacturing of biologic drugs and diversification of customers. In February this year, Mabion significantly expanded its sales activities conducted in the US market, hiring Marty Henehan as Business Development Director for North America. An analogous function for the European market has just been assumed by Nigel Stapleton. Thus, Mabion has built a professional Business Development team in the key CDMO markets - the US and European - for the implementation of the Company's strategy.

"Market practitioners with such a wealth of experience as Dr. Nigel Stapleton and Marty Henehan are not only an important reinforcement for the many sales and negotiation processes we are conducting in parallel, but also a confirmation of Mabion's attractiveness as an employer and as a future major player in the CDMO industry internationally. We have a number of strengths, from a technologically diversified manufacturing facility, to the credentials of working with a major partner like Novavax, to high competence in the development of biologic drug technology. We see this being recognized in our sales processes by an increasing number of entities. We are pleased with the dynamics of the increase in inquiries over the last few months and believe that our competence and business openness will translate into the conclusion of more contracts," adds **Adam Pietruszkiewicz, Chief Commercial Officer at Mabion S.A.**

In April 2023, Mabion adopted a long-term Strategy for 2023-2027, which aims to transform the Company into a fully integrated biologics CDMO and build its position as a recognized player in the global contract drug development and contract manufacturing market. The strategy involves significantly expanding manufacturing assets, expanding the range of technologies used, strengthening the business development department, adapting internal processes to work with multiple customers and offering a wide range of services as a fully integrated CDMO.

The first phase of the investment, scheduled for 2023-2024, primarily involves the modernization of Mabion's existing manufacturing facility in Konstancin Łódzki. As a result of the construction, assembly and installation works carried out in the second half of 2023, Mabion now has a modern and technologically diversified plant with the facility's characteristics changed from a single-product plant to one with the ability to run different processes at the same time. After the investments, the plant is equipped with a set of bioreactors with a total capacity of more than 10,000 L, of which the two largest single-use Kuhner bioreactors with orbital shaking technology have a capacity of 2,500 L each, and two more are single-use Cytiva bioreactors with classical mixing technology at 2,000 L each. In addition, Mabion offers a full range of services, covering the process from vial thawing to active substance (drug substance) and drug product (drug product) production to secondary packaging, analytics and all standard support services. As a result, Mabion is a comprehensive biologics CDMO, capable of supporting pharmaceutical companies from the early stages of drug development to large-scale commercial production.

Contact for media and individual investors

Michał Wierzchowski

+48 531 613 067

+48 22 440 14 40

michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak

+48 605 959 539

+48 22 440 14 40

mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts

Piotr Owdziej
+48 697 612 913
+48 22 440 14 40
piotr.owdziej@ccgroup.pl

Katarzyna Mucha
+48 697 613 712
+48 22 440 14 40
katarzyna.mucha@ccgroup.pl

Information about Mabion S.A.

Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organization (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the vaccine for COVID-19, which it has since steadily expanded through further services under SOWs (Statements of Work) concluded and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. According to the Strategy, announced in April 2023, the Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete Mabion's full transformation into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw S t o c k Exchange.

For more information about the Company, visit www.mabion.eu